BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...
"These data suggest that the effects of semaglutide 2.4 mg in this study may not be solely dependent on weight loss and provide important insights into the clinical effects of semaglutide 2.4 mg in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results